<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862483</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TATA-301</org_study_id>
    <nct_id>NCT02862483</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and safety of the combination of tamsulosin and tadalafil in men with lower
      urinary tract symptoms due to benign prostatic hyperplasia and Erectile Dysfunction: a
      randomized, double blinded, parallel design, active controlled, multi-center, phase 3
      clinical trial
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of total IPSS(International prostate symptom score)</measure>
    <time_frame>From baseline at week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of IIEF-EF(International Index of Erectile Function sum of questions-Erectile function) domain</measure>
    <time_frame>From baseline at week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of total IPSS(International prostate symptom score)</measure>
    <time_frame>From baseline at week 4,8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of total IPSS(International prostate symptom score) sub score (storage, voiding)</measure>
    <time_frame>From baseline at week 4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of IPSS(International prostate symptom score) QoL(Quality of Life)</measure>
    <time_frame>From baseline at week 4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Qmax(maximum urinary flow rate)</measure>
    <time_frame>From baseline at week 4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of PVR(Post Void Residual Volume)</measure>
    <time_frame>From baseline at week 4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGIC(Patient Global Impression of change) score</measure>
    <time_frame>At week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGIC(Clinician Global Impression of change) score</measure>
    <time_frame>At week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of IIEF (International Index of Erectile Function sum of questions) total score</measure>
    <time_frame>From baseline at week 4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of IIEF-IS(International Index of Erectile Function sum of questions-Intercourse satisfaction) domain score measured by IIEF question number 6~8</measure>
    <time_frame>From baseline at week 4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of OS(Overall satisfaction) domain score measured by IIEF question number13 and 14</measure>
    <time_frame>From baseline at week 4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of OF(Orgasmic function) domain score measured by IIEF question number 9 and 10)</measure>
    <time_frame>From baseline at week 4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of IIEF-EF domain(International Index of Erectile Function sum of questions-Erectile function) score measured by IIEF question number 1~5 and 15</measure>
    <time_frame>From baseline at week 4,8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of IIEF(International Index of Erectile Function) score about questions number 3 and 4</measure>
    <time_frame>From baseline at week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients who have more than 4 point about IIEF questions number 3 and 4</measure>
    <time_frame>From baseline at week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients who have increased score about IIEF questions number 3 and 4(at least 1 point) compared to the baseline</measure>
    <time_frame>From baseline at week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamsulosin 0.2mg and Tadalafil 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo for Tamsulosin 0.2mg and Tadalafil 5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin 0.2mg</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 5mg</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Tamsulosin</intervention_name>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Visit1

          -  Male aged 45 years old or older

          -  Subjects who have PSA ≤ 4.0 ng/mL Visit2

          -  Subjects who have Total IPSS score ≥ 13

          -  Subjects who have IIEF-EF domain ≤ 24 and each point below 3 in question 3 and 4

        Exclusion Criteria:

          -  Subjects who have hypersensitivity to investigational product or sulfa medications
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ji-yoon Choi</last_name>
    <email>jychoi@ildong.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Catholic university of korea, Seoul ST. Mary's Hospital.</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sae Woong Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

